DUBLIN – Faced with the high cost of completing phase III development for its Parkinson's disease drug, tozadenant (SYN115), Biotie Therapies Oyj opted to fold now and agree to a $363 million cash bid from Acorda Therapeutics Inc., rather than hold out in the hope that its value would rise later on the back of positive data.